Tuesday March 31, 2020
Home India Smartphone Pr...

Smartphone Production in India Likely To Decrease By 40% in First Half of 2020

For smartphone brands, the coronavirus pandemic will cause them to reflect, and realign their market strategies

0
//
Pixabay
For smartphone brands, the coronavirus pandemic will cause them to reflect, and realign their market strategies. Pixabay

Revising its estimates amid the novel coronavirus pandemic, a new report said on Thursday that smartphone production in India is likely to tumble by 38-40 per cent in the first half (H1) of this year.

The prospects for H2 2020, however, are brighter with shipments likely to rise 15 per cent year-on-year, thus, raising the industry spirits, said the report from CyberMedia Research (CMR)

“Our current India smartphone market assessment points to a bleak picture, with some promise in H2. We anticipate a significant drop of around 20 per cent YoY in smartphone shipments in Q1,” Prabhu Ram, Head-Industry Intelligence Group, CMR, said in a statement.

“There will be a full-blown impact in Q2 2020, with a sharp decline of around 28 per cent YoY,” Ram added. Both supply and demand have been hit and while the OEMs could tide over the initial wave of coronavirus crisis in January and February with adequate component supplies, the closure of smartphone factories in India has dented recovery prospects for H1.

Samsung, Apple, Xiaomi, Vivo, Oppo, Realme and others have temporarily shut production in India amid the 21-day nationwide lockdown. On the demand side, with the coronavirus scare, offline channels are massively impacted with sales down by 55-60 per cent.

“If one were to go by China’s experience, the online channels made-up for the deficit, incurred in offline channels. However, in the Indian context, with the initial 21-day lockdown in force, we are now looking at a rather uncertain future.

Smartphone
Revising its estimates amid the novel coronavirus pandemic, a new report said on Thursday that smartphone production in India is likely to tumble by 38-40 per cent in the first half (H1) of this year. Pixabay

“That said, we believe online has the potential to pick-up in terms of sales during mid- to late- Q2 and beyond,” said Amit Sharma, Manager-Research, CMR.

For smartphone brands, the coronavirus pandemic will cause them to reflect, and realign their market strategies.

ALSO READ: Digital India Faces Several Challenges Amidst Coronavirus Lockdown

“In H2, the smartphone market will recover, and perform better in the run-up to festive season and beyond. The pent-up consumer demand will be high, and with the right messaging from smartphone brands, consumers would seek to upgrade their value for money, and premium smartphones,” Ram noted. (IANS)

Next Story

Can TB Vaccine Fight COVID-19? Here is the Answer

TB vaccine a potential new tool to fight COVID-19: Study

0
vaccine
Researchers have found that Bacillus Calmette-Guerin (BCG), a vaccine for tuberculosis (TB), could be a potential new tool in the fight against the disease. Pixabay

Examining how the COVID-19 has impacted different countries, researchers have found that Bacillus Calmette-Guerin (BCG), a vaccine for tuberculosis (TB), could be a potential new tool in the fight against the disease.

The study that appeared in the pre-print repository medRxiv, proposed that national differences in COVID-19 impact could be partially explained by the different national policies respect to BCG childhood vaccination.

The BCG vaccine has existed for almost a century and is one of the most widely used of all current vaccines.

Please follow NewsGram on Twitter to get updates on the latest news

BCG vaccine has a documented protective effect against meningitis and disseminated TB in children.

vaccine
The BCG vaccine has existed for almost a century and is one of the most widely used of all current vaccines. Pixabay

It has also been reported to offer broad protection to respiratory infections.

For the study, the researchers compared large number of countries BCG vaccination policies with the morbidity and mortality for COVID-19.

“We found that countries without universal policies of BCG vaccination (Italy, the Netherlands, the US) have been more severely affected compared to countries with universal and long-standing BCG policies,” said the study conducted by researchers from New York Institute of Technology (NYIT) College of Osteopathic Medicine in the US.

The number of confirmed coronavirus cases in the US has increased to 142,502, the highest in terms of infections globally, according to the latest tally from Johns Hopkins University’s Center for Systems Science and Engineering (CSSE).

The CSSE data showed that at least 34,026 people have died due to the disease in the country.

In Italy, which is one of the worst affected countries, 10,779 people have died due to COVID-19.

In this latest study on impact of BCG vaccination on COVID-19, researchers also found that countries that have a late start of universal BCG policy, for example, Iran had high mortality, consistent with the idea that BCG protects the vaccinated elderly population.

“There was a positive significant correlation between the year of the establishment of universal BCG vaccination and the mortality rate, consistent with the idea that the earlier that a policy was established, the larger fraction of the elderly population would be protected,” said the study.

vaccine
BCG vaccine has a documented protective effect against meningitis and disseminated TB in children. Pixabay

“For instance, Iran has a current universal BCG vaccination policy but it just started in 1984, and has an elevated mortality with 19.7 deaths per million inhabitants.

“In contrast, Japan started its universal BCG policy in 1947 and has around 100 times less deaths per million people, with 0.28 deaths. Brazil started universal vaccination in 1920 and also has an even lower mortality rate of 0.0573 deaths per million inhabitants,” the resulst showed.

Iran announced 2,901 new COVID-19 cases on Sunday as the total number of confirmed cases soared to 38,309. Also, the death toll from the disease reached 2,640 in Iran, while 12,391 patients have recovered.

Please follow NewsGram on Facebook to get updates on the latest news

As the numbers of tuberculosis cases dropped in the late 20th century, several middle high and high-income countries in Europe dropped the universal BCG policy between years 1963 and 2010.

“The combination of reduced morbidity and mortality makes BCG vaccination a potential new tool in the fight against COVID-19,” the researchers concluded.

Also Read- Taking Care of Finances Amid Coronavirus Crisis

Gonzalo H. Otazu of NYIT is the corresponding author of the study.

The COVID-19 death toll in Europe climbed to over 21,000 out of more than 360,000 confirmed cases. (IANS)